The company’s net income climbed 23.5% to KRW 85.3 billion for the first six months of 2026, even as operating profit growth leveled to 8.4%. This slight cooling in profit margins stems from heavy strategic investment into U.S. direct sales operations and marketing initiatives designed to cement long-term international dominance.

Global performance remains the primary engine, with overseas sales now accounting for 67% of total revenue. Sales in the Americas more than doubled during the first half, while Asia-Pacific and European markets saw mid-to-high 20% growth. Domestically, Hugel continues to fend off stiff competition in the K-aesthetics sector, where its combined sales of toxin and fillers rose 2.5% to KRW 53.5 billion. The cosmetics division also contributed significantly, posting a 31.7% increase in first-half sales to reach KRW 39 billion.